🔴 We are now live with an engaging presentation by Dr. Valerie Taly, PhD, Co-founder, President, and Chief Scientific Officer of METHYS Dx, and Senior Researcher at CNRS, University Paris Cité, France.
Presentation: Combining Methylation Markers and Digital PCR for Real-Time Cancer Follow-Up
In this session, Dr. Taly is showcasing how the integration of DNA methylation biomarkers with digital PCR technologies is advancing the next generation of liquid biopsy for cancer management.
Her presentation highlights how highly sensitive epigenetic biomarkers can improve the detection and monitoring of cancer, enabling clinicians to accurately assess tumor burden, identify minimal residual disease (MRD), detect early recurrence, and monitor treatment response through minimally invasive blood-based testing.
Drawing on her pioneering work in molecular diagnostics and epigenetic liquid biopsy, Dr. Taly is demonstrating how combining advanced methylation profiling with digital PCR offers greater precision and clinical utility, bringing personalized cancer monitoring closer to routine clinical practice.
This insightful session highlights the growing role of epigenetic biomarkers in precision oncology and the future of real-time, patient-centered cancer care.
We sincerely thank Dr. Valerie Taly for sharing her expertise and our global audience for joining us in this exciting scientific discussion.
This conference is organized by Impact Research Communications (IRC)
More info: https://liquidbio.ircconferences.net/ | Advances in Liquid Biopsy
